Gastrointestinal Stromal Tumors
Conditions
Interventions
Case series:adjuvant Gastrointestinal Stromal Tumors after Imatinib Mesylate
Sponsors
Henan Provincial People's Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 to 70 years male and female; 2. Gastrointestinal stromal tumor was confirmed by histopathological, and immunohistochemical detection of CD117 and / or DOG-1 was positive; 3. The types of gene mutiotion:exons 9 ,11 ,13 and 17 of the c-kit gene and exons 12 and 18 of the PDGFRA gene; 4. The lesions of Gastrointestinal Stromal Tumors have been completely resected (R0), and the risk grade is intermediate risk and high risk; 5. Physical condition was 0-2 points with ECOG; 6. The patient gaves informed consent and signs a written consent; 7. Patient compliance was good and voluntarily accepted follow-up, treatment, laboratory tests, and other research steps as planned.
Exclusion criteria
Exclusion criteria: 1. The PDGFRA gene exon 18 D842V mutation and the wild type GIST. 2. AST and / or ALT > 2.5 × ULN. 3. Serum total bilirubin > 1.5 x ULN. 4. The absolute count of neutrophils (ANC) is 1.0×ULN. 6. Past Medical History:Brain or pial disease such as brain metastasis, spinal cord compression, and cancerous meningitis and other malignant tumors. 7. Any of the following conditions within 12 months prior to enrollment: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass surgery, symptomatic congestive heart failure, or cerebrovascular accident. 8. Serum HIV antibody was positive. 9. The patient is Currently participating in other clinical trials. 10. Women pregnant or lactating or have fertility but have not used contraception. 11. Patients with other serious acute or chronic physical or mental problems, or abnormal laboratory tests, may increase the risk of participating in the study or use of drugs, or interfere with the judgment of the results of the study, and the researcher judges that it is not suitable for participation in the study; 12. Treated with tyrosine kinase inhibitors including Imatinib Mesylate previously.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tumor recurrence; | — |
Countries
China
Contacts
Public ContactPeichun Sun
Henan Provincial People's Hospital
Outcome results
None listed